UPDATE: Cantor Fitzgerald Maintains Overweight On PTC Therapeutics, Raises Target To $81 As Firm Notes 'Risdiplam will be a blockbuster' Adjusts 'PoS for risdiplam to 100% from 75% and factored in the milestones in the coming years'